PD-L1 inhibitor
Drug timelines are a Plus or Pro feature.
13 regulatory and trial events tracked for PD-L1 inhibitor, covering 2018-07-11 to 2026-03-03. Get the full timeline:
Most recent: Clinical Trial Update: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) [Phase 1]